Outlook Therapeutics (OTLK) Accounts Payables (2015 - 2026)

Outlook Therapeutics (OTLK) has 12 years of Accounts Payables data on file, last reported at $13.6 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $13.6 million, up 75.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.6 million (up 75.58% YoY), and the FY2025 annual result was $10.2 million, up 27.9% from the prior year.
• Accounts Payables climbed to $13.6 million in Q1 2026 per OTLK's latest filing, from $7.3 million in the prior quarter.
• Over five years, Accounts Payables peaked at $13.6 million in Q1 2026 and troughed at $2.5 million in Q2 2022.
• A 5-year average of $6.6 million and a median of $5.6 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables surged 250.33% in 2024, then tumbled 39.98% in 2025.
• A 5-year view of Accounts Payables shows it stood at $4.2 million in 2022, then declined by 16.54% to $3.5 million in 2023, then surged by 250.33% to $12.2 million in 2024, then plunged by 39.98% to $7.3 million in 2025, then jumped by 86.32% to $13.6 million in 2026.
• Business Quant data shows OTLK's Accounts Payables at $13.6 million in Q1 2026, $7.3 million in Q4 2025, and $10.2 million in Q3 2025.